Transfusion dependent thalassemia
Drug research and approvals for transfusion dependent thalassemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 26 studies of transfusion dependent thalassemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 26
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 26 recruiting on ClinicalTrials.gov ↗- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent…NCT07884773 · Phase 3 · Khyber Medical University Peshawar · starts Oct 12, 2026
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With…NCT07506863 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Sep 24, 2026
- A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or…NCT07517133 · Phase 3 · Agios Pharmaceuticals, Inc. · starts Sep 1, 2026
- Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemiaNCT07680803 · Phase 2 · Fondazione Telethon · starts Jul 6, 2026
- A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastNCT07215975 · Not reported · Bristol-Myers Squibb · starts Jun 26, 2026
- Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT PatientsNCT07338344 · Phase 2 · Rongrong Liu · starts Feb 1, 2026
- Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesNCT06647979 · Phase 1 · Daniel Bauer · starts Dec 1, 2025
- Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDNCT07207577 · Not applicable · Centre Hospitalier Metropole Savoie · starts Sep 4, 2025
- A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaNCT06772766 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Dec 30, 2024
- Long-term Follow-up Study of BRL-101 for TDTNCT06298630 · Not reported · Bioray Laboratories · starts Dec 8, 2024
Trials Authorized in Canada
Newest first; search them all in Canada trials| Apr 6, 2022 | A multicenter study to evaluate the safety, tolerability, and efficacy of a single dose of autologous clustered regularly interspaced short palindromic repeats…EDIT-301 / MOZOBIL / FILGRASTIM | EDITAS MEDICINE, INC. | Ongoing |
| Oct 28, 2021 | A phase 3 study to evaluate the safety and efficacy of a single dose of ctx001 in pediatric subjects with transfusion-dependent ¿-thalassemiaEXAGAMGLOGENE AUTOTEMCEL (CTX001) / BUSULFAN / PLERIXAFOR | Vertex Pharmaceuticals | Ongoing |
| Jul 12, 2018 | A phase 1/2 study of the safety and efficacy of a single dose of autologous crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells (hhspcs)…CTX001/ BUSULFAN / PLERIXAFOR | CRISPR THERAPEUTICS INC | Ongoing |
| Dec 5, 2014 | Multicenter, open-label, dose-escalation study of sp 420 in subjects with transfusion-dependent thalassemiaSP-420 | SIDERIS PHARMACEUTICALS INC | Ongoing |
| Jul 3, 2014 | The use of the calcium channel blocker amlodipine as an adjuvant treatment to iron chelation for the prevention of iron overload cardiomyopathy in patients…AMLODIPINE | UNIVERSITY HEALTH NETWORK | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jan 23, 2013 | Exjade; Jadenu SprinklesTreatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and… | Novartis Pharmaceuticals Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA